Real-World Safety Profile of Mirvetuximab Soravtansine: A Population-Based Pharmacovigilance Study Leveraging FAERS and EudraVigilance Databases.
PURPOSE Mirvetuximab soravtansine (MIRV) is the first FDA-approved antibody-drug conjugate targeting folate receptor-α (FRα)-positive platinum-resistant ovarian cancer. Despite its clinical adoption, comprehensive post-marketing real-world evidence regarding its safety profile remains limited. This study aimed to syste...